Skip to main content

Advertisement

SpringerLink
Log in

Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Malign Peritoneal Mesothelioma: Clinical Aspects and Therapeutic Perspectives

  • Review Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Malignant mesotheliomas develop commonly in the pleural cavity and second mesotheliomas arise in the peritoneal cavity (20–30%). Most frequent symptoms/signs are ascites (77%) and abdominal pain (f69%). Biopsy in these patients should be taken from the peritoneum by invasive method (laparotomy, laparoscopy and core needle biopsy). The couplet of systemic pemetrexed and cisplatin had an overall response rate of approximately 25% and a median overall survival of approximately 1 year. Patients with a good general condition, epithelioid histology, nonabdominal disease, complete or near cytoreduction (CC0/CC1), low Ki67 proliferative index and peritoneal cancer index (PCI) score less than 17 should be administered through cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) rather than palliative systemic chemotherapy. The survival rate with Ki67 ≤ 9% is higher than patients with Ki67 > 9. The basic principles of the CRS are not different from other peritoneal carcinomas. The combination of cisplatin and doxorubicin is the best recommended drug regimen for the hyperthermic intraperitoneal chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moolgavkar SH, Meza R, Turim J (2009) Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 20:935–944

    Article  Google Scholar 

  2. Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18:827–834

    Article  CAS  Google Scholar 

  3. Enomoto LM, Shen P, Levine EA, Votanopoulos KI (2019) Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Manag Res 11:4231–4241

    Article  CAS  Google Scholar 

  4. Bridda A, Padoan I, Mencarelli R, Frego M (2007) Peritoneal mesothelioma: a review. Medscape Gen Med 9:32

    Google Scholar 

  5. Henley SJ, Larson TC, Wu M et al (2013) Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health 19:1–10

    Article  Google Scholar 

  6. Li CY, Alexander HR Jr (2018) Peritoneal metastases from malignant mesothelioma. Surg Oncol Clin N Am 27:539–549

    Article  Google Scholar 

  7. Boffetta P (2007) Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 18:985–990

    Article  CAS  Google Scholar 

  8. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S (2013) Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol 66:847–853

    Article  Google Scholar 

  9. E Canbay, Y Yonemura (2015) Peritoneal surface malignancies: a curative approach Springer, ISBN: 978-3-319-12936-5.

  10. Nunez MF, Sardi A, Jimenez W, Nieroda C, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V (2015) Port-site metastases is an independent prognostic factor in patients with peritoneal carcinomatosis. Ann Surg Oncol 22:1267–1273

    Article  Google Scholar 

  11. Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, van der Speeten K, Glehen O, Kepenekian V, Kusamura S, Alyami MS, André T, Barrios-Sanchez P, Baumgartner JM, Bhatt A, Ben-Yaacov A, Bertulli R, Braess J, Burger JWA, Cascales-Campos P, Cashin P, Cecil, P T, Ceelen WP, Creemers GJ, Cortes-Guiral D, Dayal S, de Simone M, di Bartolomeo M, Dube P, Flatmark K, Foster JM, Goere D, Gonzales-Bayon L, Heriot A, Hewett PJ, Hsieh MC, Hubner M, Kok NFM, Larsen SG, Lehmann K, Li Y, Loggie BW, Lutton N, Ly J, Lynch C, Lyra M, Mehta S, Mohamed F, Morris DL, Nissan A, Nowacki MS, Pande PK, Park EJ, Peron J, Perry DJ, Pietrantonio F, Piso P, Pocard M, Quadros C, Rajan F, Rau B, Reymond MA, Thuss-Patience P, Sardi A, Sideris L, Sinn M, Sokmen S, Somashekhar SP, Spiliotis JD, Sugarbaker PH, Syk I, Tentes AA, Teo MCC, Turaga KK, Valle M, Verwaal VJ, Wilson MS, Yarema RR, Yonemura Y, Yu Y (2019) The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. Eur J Surg Oncol 47:4–10. https://doi.org/10.1016/j.ejso.2019.03.012

    Article  PubMed  Google Scholar 

  12. Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M (2016) The role of Ki67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23(5):1468–1473. https://doi.org/10.1245/s10434-015-4962-9 Epub 2015 Nov 16

    Article  PubMed  Google Scholar 

  13. Pillai K, Pourgholami MH, Chua TC, Morris DL (2013) Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res 3(4):411–423

    PubMed  PubMed Central  Google Scholar 

  14. Pezzuto F, Serio G, Fortarezza F, Scattone A, Caporusso C, Punzi A, Cavone D, Pennella A, Marzullo A, Vimercati L (2020) Prognostic value of Ki67 percentage, WT-1 expression and p16/CDKN2A deletion in diffuse malignant peritoneal mesothelioma: a single-centre cohort study. Diagnostics (Basel) 10(6):386. https://doi.org/10.3390/diagnostics10060386

    Article  Google Scholar 

  15. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10:1240–1242

    Article  Google Scholar 

  16. Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, Katsanos KH, Christodoulou DK (2018) Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol 31:659–669

    PubMed  PubMed Central  Google Scholar 

  17. Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA (2010) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 17:2720–2727

    Article  Google Scholar 

  18. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O (2006) Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 13:405–412

    Article  CAS  Google Scholar 

  19. Chua TC, Yan TD, Morris DL (2009) Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 99:109–113

    Article  Google Scholar 

  20. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker (2000) PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 87:1587–1593

    Article  CAS  Google Scholar 

  21. Tudor EC, Chua TC, Liauw W, Morris DL (2010) Risk factors and clinicopathological study of prognostic factors in the peritoneal mesothelioma. Am Surg 76:40

    Google Scholar 

  22. Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20:1093–1100

    Article  Google Scholar 

  23. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560–4567

    Article  CAS  Google Scholar 

  24. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I (2013) A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol 20:555–561

    Article  Google Scholar 

  25. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242

    Article  Google Scholar 

  26. Yano H, Moran BJ, Cecil TD, Murphy EM (2009) Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol 35:9

    Article  Google Scholar 

  27. Yonemura Y, Ishibashi H, Canbay E, Sako S, Tsukiyama G, Mizumoto Y, Ichinose M, Takao N, Yabuki S, Tanaka H, Hirano M, Fushida S, Endou Y (2012) Treatment results of diffuse malignant peritoneal mesothelioma. Gan To Kagaku Ryoho 39:2416–2419

    PubMed  Google Scholar 

  28. Elias D, Bedard V, Bouzid T, Duvillard P, Kohneh-Sharhi N, Raynard B, Goere D (2007) Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol 31:784–788

    Article  Google Scholar 

  29. Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA (2014) Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 21(4):1159–1165. https://doi.org/10.1245/s10434-013-3358-y

    Article  PubMed  Google Scholar 

  30. Chandramohan A, Thrower A, Shah N, Mohamed F (2017) Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol 90(1079):20170361. https://doi.org/10.1259/bjr.20170361

    Article  PubMed  PubMed Central  Google Scholar 

  31. Malgras B, Gayat E, Aoun O et al (2018) Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol 25:3271–3279

    Article  Google Scholar 

  32. Gilani SNS, Mehta A, Garcia-Fadrique A, Rowaiye B, Jenei V, Dayal S, Chandrakumaran K, Carr N, Mohamed F, Cecil T, Moran B (2018) Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperth 34(5):578–584. https://doi.org/10.1080/02656736.2018.1434902

    Article  Google Scholar 

  33. Broeckx G, Pauwels P (2018) Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res 7:537–542

    Article  CAS  Google Scholar 

  34. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190–9198

    Article  CAS  Google Scholar 

  35. Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M (2018) Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. Eur J Surg Oncol 44:792–798

    Article  Google Scholar 

  36. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin level. N Engl J Med 353(15):1564–1573

    Article  CAS  Google Scholar 

  37. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL (2008) Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 26:3567–3572

    Article  CAS  Google Scholar 

  38. Turner KM, Varghese S, Alexander HR (2011) Surgery for peritoneal mesothelioma. Curr Treat Options in Oncol 12:189–200

    Article  Google Scholar 

  39. Kusamura S, Kepenekian V, Villeneuve L, Lurvink RJ, Govaerts K (2020) Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol S0748-7983(20):30113-X. https://doi.org/10.1016/j.ejso.2020.02.011

    Article  Google Scholar 

  40. Sugarbaker PH (2018) Update on the management of malignant peritoneal mesothelioma. Transl Lung Cancer Res 7:599–608

    Article  Google Scholar 

  41. Albanese AM, Albanese EF, Miño JH, Gómez E, Gómez M, Zandomeni M, Merlo AB (2009) Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas. Surg Radiol Anat 31:369–377

    Article  Google Scholar 

  42. Ludeman L, Shepherd NA (2007) Pathological evaluation and implications of serosal involvement in gastrointestinal cancer. Recent Results Cancer Res 169:25–38

    PubMed  Google Scholar 

  43. Baratti D, Kusamura S, Cabras AD, Deraco M (2012) Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol 19:1416–1424

    Article  Google Scholar 

  44. Meyer MA (1973) Distribution of intraabdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Therapy, Nucl Med 119:198–206

    Article  Google Scholar 

  45. Eltabbakh GH, Mount SL (2002) Lymphatic spread among women with primary peritoneal carcinoma. J Surg Oncol 81:126–131

    Article  Google Scholar 

  46. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22:1686–1693

    Article  Google Scholar 

  47. Schuitevoerder D, Izquierdo FJ, Plana A, Nash GM, Fernandez LJ, Kluger MD et al (2020) The Chicago Consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Ann Surg Oncol 27:1774–1779

    Article  Google Scholar 

  48. Alexander HR, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS et al (2013) Treatment factors associated with long- term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153:779–786

    Article  Google Scholar 

  49. Ihemelandu C, Bijelic L, Sugarbaker PH (2015) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ann Surg Oncol 22:1680–1685

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Ege University School of Medicine, İzmir, Turkey

    Taylan Özgür Sezer, Almir Miftari, Özgür Fırat & Sinan Ersin

Authors
  1. Taylan Özgür Sezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Almir Miftari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Özgür Fırat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sinan Ersin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study Design: Taylan Ö. Sezer. Data Collection: Taylan Ö. Sezer and Almir Miftari. Data Interpretation: Taylan Ö. Sezer, Özgür Fırat and Sinan Ersin. Manuscript Preparation: Taylan Ö. Sezer and Almir Miftari. Literature Search: Taylan Ö. Sezer, Sinan Ersin and Özgür Fırat.

Corresponding author

Correspondence to Taylan Özgür Sezer.

Ethics declarations

Conflict of Interest

All authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sezer, T.Ö., Miftari, A., Fırat, Ö. et al. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Malign Peritoneal Mesothelioma: Clinical Aspects and Therapeutic Perspectives. Indian J Surg 84, 21–27 (2022). https://doi.org/10.1007/s12262-021-02809-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-021-02809-y

Keywords

Search

Navigation